Status:
COMPLETED
Peginterferon and Ribavirin on Virologic and Immunologic Parameters in Hepatitis C Mono- and Coinfected Patient (PRIVICOP)
Lead Sponsor:
UMC Utrecht
Collaborating Sponsors:
Hoffmann-La Roche
Conditions:
Hepatitis C
HIV Infections
Eligibility:
All Genders
18+ years
Brief Summary
Hepatitis C and HIV infect worldwide millions of people leading to a high rate of coinfected patient with eventually liver cirrhosis and endstage liver disease. With the currently best available thera...
Detailed Description
background: each year the Hepatitis C (HCV) and the human immunodeficiency virus (HIV) infect worldwide millions of people. In the western world coinfection of HIV with HCV mainly exists in intravenou...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- All patients where the treating physicians decides to start treatment with peginterferon and ribavirin for treatment of hepatitis C
- HCV mono-infection or HCV / HIV coinfection
- Genotype 1
- Compliant for outpatient visits
Exclusion
Key Trial Info
Start Date :
August 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00150904
Start Date
August 1 2005
End Date
January 1 2009
Last Update
February 16 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center Utrecht
Utrecht, Utrecht, Netherlands, 3584 CX